Please assess the completion status of the following clinical trial:

Trial Title: Baerveldt Plate Area Comparison (BPAC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 18~* Intra-Ocular Pressure (IOP) \> 18 mm Hg and \< 40 mm Hg on medical therapy~* Previous ocular surgery limited to (cataract, corneal transplant, trabeculectomy, vitrectomy)~* Consent signed~Exclusion Criteria:~* Unwilling or unable to give consent, unwilling to accept randomization, or unable to return for scheduled protocol visits~* Pregnant or nursing~* Neuro-Linguistic Programming (NLP) vision~* Iris neovascularization or proliferative retinopathy~* Epithelial or fibrous downgrowth~* Chronic or recurrent uveitis~* Steroid-induced glaucoma~* Severe posterior blepharitis~* Previous cyclodestructive procedure~* Conjunctival scarring from prior ocular trauma or cicatrizing disease (e.g. Stevens Johnson syndrome, ocular pemphigoid) precluding Baerveldt implantation.~* Functionally significant cataract~* Need for Baerveldt implant combined with other ocular procedures (ie cataract surgery,penetrating keratoplasty, or retinal surgery) or anticipated need for additional ocular surgery~* Prior glaucoma drainage device (tube) implant~* Prior retinal surgery with remaining silicone oil~* Prior scleral buckling procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A - Baerveldt 250 mm2 (Type: EXPERIMENTAL): Patients receiving Baerveldt 250 mm2
- Arm B - Baerveldt 350 mm2 (Type: EXPERIMENTAL): Patients receiving Baerveldt 350 mm2

Based on this trial design, predict the completion outcome and termination type (if applicable).